How Much Is Corpremans Clinical Trial Consultancy AB Worth?
Corpremans Clinical Trial Consultancy AB - Company Valuation
Combines filings, registry risk signals, and versioned market evidence. Learn More ↗ Opens in a New Tab
Enterprise Value
15,114,331 kr
- Range
- 11,082,619 kr–26,765,421 kr
- Evidence StrengthShows how strongly available evidence supports the result. Learn More ↗ Opens in a New Tab
- Low
- Based on FY
- 2025
- Valuation Date
- Business StrengthSummarises business strength from financial and public-record signals. Learn More ↗ Opens in a New Tab
- B+
- Altman Z″Indicates financial-distress risk. A higher score is stronger. Learn More ↗ Opens in a New Tab
- 7.84
- Risks
- Insufficient Data
Scope & Evidence
- Company
- Corpremans Clinical Trial Consultancy AB
- Registration
- SE · 5593634412
- Covers
- Not stated in the filing
- Filings Used
- 4 · FY 2025, 2024, 2023, 2022
Industry: NACE 72 · 3 Europe industry cohorts
Methodology & Assumptions
- Industry EV / EBITDA
- 15.9×
- Industry Revenue Multiple
- 3.95×
- Revenue Multiple
- 3.95×
- Enterprise Value
- 15,114,331 kr
- Value Before Discount
- 15,114,331 kr
Key Ratios
- Current RatioCurrent assets divided by current liabilities. Learn More ↗ Opens in a New Tab
- 3.83×
- Quick RatioCurrent assets minus inventory, divided by current liabilities. Learn More ↗ Opens in a New Tab
- -
- Debt / EquityTotal liabilities divided by equity. Learn More ↗ Opens in a New Tab
- 1.09×
- Equity RatioEquity as a share of total assets. Learn More ↗ Opens in a New Tab
- 47.9%
- Interest CoverageEBIT divided by interest expense. Learn More ↗ Opens in a New Tab
- ≥ 100.00×
- Gross MarginGross profit as a share of revenue. Learn More ↗ Opens in a New Tab
- -
- Net Profit MarginNet profit as a share of revenue. Learn More ↗ Opens in a New Tab
- 17.3%
- Return on EquityNet profit as a share of owners' equity. Learn More ↗ Opens in a New Tab
- 53.6%
- Return on AssetsNet profit as a share of total assets. Learn More ↗ Opens in a New Tab
- 25.7%
- Revenue CAGRAverage annual revenue growth over the available period. Learn More ↗ Opens in a New Tab
- 48.5%
Asset Distribution
CashReceivablesOther Assets
Liability Maturity
Short-TermLong-Term
3-Year Revenue Scenarios
14m kr
10.5m kr
7m kr
3.5m kr
0 kr
202620272028
OptimisticBaseConservative
A comparison between a company and a defined peer group. Learn More ↗ Opens in a New Tab
Revenue vs Industry Peers
- RISE Research Institutes of Sweden AB
- 4,394,000,000 kr
- Amgen Aktiebolag
- 2,783,154,000 kr
- Corpremans Clinical Trial Consultancy AB ★
- 4,425,467 kr
- Dellstad Konsult AB
- 1,365,300 kr
- Nelara Medical AB
- 196,820 kr
- KarOlin Medical AB
- 102,000 kr
Earnings before interest, taxes, depreciation, and amortisation. Learn More ↗ Opens in a New Tab
Revenue, Profit & EBITDA
6m kr
4.5m kr
3m kr
1.5m kr
0 kr
2022202320242025
RevenueNet Profit
Versus Industry Median
6m kr
4.5m kr
3m kr
1.5m kr
0 kr
RevenueNet Profit
This CompanyIndustry Median